{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:08:42Z","timestamp":1793610522668,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Clinical trials have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are closely associated with hepatic fibrosis and steatosis by FibroScan. This paper aimed at evaluating the effects of SGLT2i on hepatic fibrosis and steatosis, which are presented as liver stiffness measurement (LSM) and controlled attenuation parameter (CAP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure Database, China Science and Technology Journal Database, and Wanfang Database were searched for randomized clinical trials from database establishment to 30 November 2022 with no language restrictions. The risk of bias was evaluated by Collaboration Handbook. Software Stata 17 and Review Manager (version 5.3) were used for meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of eight articles including 686 patients were included. Compared with the control group, our results showed that SGLT2i could lower levels of LSM [MD = \u22120.82, 95%CI (\u22121.38, \u22120.25), p = 0.005] and CAP [MD = \u221212.80, 95%CI (\u221220.57, \u22125.03), p = 0.001]. Further subgroup analyses indicated that SGLT2i presented more advantages on longer treatment duration and more serious steatosis in decreasing LSM. For CAP, SGLT2i exhibited a clear advantage in subgroup analyses of longer treatment duration, younger people, dapagliflozin, worse fibrosis, and steatosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SGLT2i could reduce LSM and CAP in contrast to other antihyperglycemic drugs. However, the included studies are not definitive, and well-designed, more multi-centered, blinded randomized clinical trials are warranted to definitively establish reliable evidence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1144838","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:12:10Z","timestamp":1677654730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Peipei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenning","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): A novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29489","article-title":"Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease","volume":"67","author":"Vuppalanchi","year":"2018","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27844","article-title":"The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease","volume":"62","author":"Petta","year":"2015","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12649","article-title":"Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis","volume":"46","author":"Fujimori","year":"2016","journal-title":"Hepatol Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28843","article-title":"Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values","volume":"65","author":"Petta","year":"2017","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"B11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2018.10.013","article-title":"Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease","volume":"71","author":"Handzlik","year":"2019","journal-title":"Pharmacol Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2020.102173","article-title":"SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: A systematic review","volume":"6","author":"Dwinata","year":"2020","journal-title":"Clin Exp Hepatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e19046","DOI":"10.7759\/cureus.19046","article-title":"Pioglitazone for the treatment of metabolic-associated fatty liver disease in people living with HIV and prediabetes","volume":"13","author":"Kamolvisit","year":"2021","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i26.3243","article-title":"Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis\/fibrosis\/inflammation and redox balance in non-alcoholic fatty liver disease","volume":"28","author":"Bellanti","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.923606","article-title":"GLP-1 RAs and SGLT-2 inhibitors for insulin resistance in nonalcoholic fatty liver disease: Systematic review and network meta-analysis","volume":"13","author":"Yan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107815","article-title":"Efficacy and safety of cinnamon in type 2 diabetes mellitus and pre-diabetes patients: A meta-analysis and meta-regression","volume":"156","author":"Deyno","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"Article 259","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: A 24-week randomized controlled trial","volume":"9","author":"Han","year":"2020","journal-title":"J Clin Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.spl.155","article-title":"Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"82","author":"Hu","year":"2020","journal-title":"Indian J Pharm Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.14009\/j.issn.1672-2124.2022.09.009","article-title":"Effects of dapagliflozin combine with liraglutide on inflammatory factors, glucolipid metabolism and liver function in patients with type 2 diabetes combined with non-alcoholic fatty liver disease","volume":"22","author":"Chu","year":"2022","journal-title":"Eval Anal Drug-Use Hospitals China"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0319","article-title":"Comparison of serum ketone levels and cardiometabolic efficacy of dapagliflozin versus sitagliptin among insulin-treated Chinese patients with type 2 diabetes mellitus","volume":"46","author":"Lee","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B32","volume-title":"Clinical observation of polyethylene glycol loxenatide and dapagliflozin in the treatment of type 2 diabetes mellitus complicated with NAFLD","author":"Tang","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002027","article-title":"Non-invasive tests of non-alcoholic fatty liver disease","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2021.06.002","article-title":"Quantification of liver fat content with ultrasound: A WFUMB position paper","volume":"47","author":"Ferraioli","year":"2021","journal-title":"Ultrasound Med Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: A new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03157-x","article-title":"Ultrasound and FibroScan(\u00ae) controlled attenuation parameter in patients with MAFLD: head to head comparison in assessing liver steatosis","volume":"78","author":"Salmi","year":"2022","journal-title":"Endocrine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"51","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-\u03b1, IL-1\u03b2, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.17894","article-title":"Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study","volume":"32","author":"Poonawala","year":"2000","journal-title":"Hepatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the burden of nonalcoholic fatty liver disease in a united states cohort of veterans","volume":"14","author":"Kanwal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American association for the study of liver diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: A new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin Diabetes"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.836455","article-title":"Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.08.017","article-title":"The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis","volume":"54","author":"Mo","year":"2022","journal-title":"Dig Liver Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v22i3.42","article-title":"Empagliflozin for the treatment of non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials","volume":"22","author":"Tang","year":"2022","journal-title":"Afr Health Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1144838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:12:16Z","timestamp":1677654736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1144838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":50,"alternative-id":["10.3389\/fendo.2023.1144838"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1144838","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"article-number":"1144838"}}